Different intravitreal properties of three triamcinolone formulations and their possible impact on retina practice

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 3, 2013, Pages 2178-2185

  Chen, Hao ^a   Sun, Shumao ^a   Li, Jie ^a   Du, Wennan ^a   Zhao, Chunhui ^a   Hou, Jiangping ^a   Xu, Yu ^a   Cheng, Lingyun ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE;

AMPOULE; ANIMAL EXPERIMENT; AQUEOUS HUMOR; ARTICLE; DISSOLUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KINETICS; MICRODIALYSIS; NONHUMAN; OPHTHALMOSCOPY; OSMOLARITY; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RABBIT; RETINA; SOLUBILITY; SURGICAL MICROSCOPE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VISION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AQUEOUS HUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; INTRAVITREAL INJECTIONS; PARTICLE SIZE; RABBITS; RETINA; TRIAMCINOLONE; VITREOUS BODY;

EID: 84875676955     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11460     Document Type: Article

References (28)

1. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Amer J Ophthalmol. 2004;138:740-743.
2. Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005; 112:1916. e1911-1916. e1917.
3. Veritti D, Di Giulio A, Sarao V, Lanzetta P. Drug safety evaluation of intravitreal triamcinolone acetonide. Expert Opin Drug Saf. 2012;11:331-340.
4. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127:1101-1114.
5. Wang YS, Li X, Wang HY, Zhang ZF, Li MH, Su XN. Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema. Chin Med J (Engl). 2011;124:352-358.
6. Moshfeghi AA, Nugent AK, Nomoto H, Sanislo SR, Kitchens JW, Moshfeghi DM. Triamcinolone acetonide preparations: impact of crystal size on in vitro behavior. Retina. 2009;29: 689-698.
7. Zacharias LC, Estrago-Franco MF, Ramirez C, et al. The effects of commercially available preservative-free FDA-approved triamcinolone (Triesence(R) on retinal cells in culture. J Ocul Pharmacol Ther. 2011;27:143-150.
8. Smiddy WE. Clinical applications of cost analysis of diabetic macular edema treatments. Ophthalmology. 2012;119:2558-2562.
9. Bakri SJ, Edwards AO, Couch SM. Noninfectious endophthalmitis occurring after intravitreal Triesence injection. Retin Cases Brief Rep. 2009;3:316-318.
10. Diabetic Retinopathy Clinical Research Network. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127:245-251.
11. Spitzer MS, Ziemssen F, Yoruk E, Bartz-Schmidt KU, Schultheiss M, Szurman P. Preservative-free triamcinolone versus purified triamcinolone preparations [in German]. Klin Monbl Augenheilkd. 2011;228:626-630.
12. Ding X, Li J, Hu X, Yu S, Pan J, Tang S. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina. 2011;31:838-845.
13. Zacharias LC, Lin T, Migon R, et al. Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide. Retina. 2012;33:522-531.
14. Macha S, Mitra AK. Ocular pharmacokinetics in rabbits using a novel dual probe microdialysis technique. Exp Eye Res. 2001; 72:289-299.
15. Duvvuri S, Rittenhouse KD, Mitra AK. Microdialysis assessment of drug delivery systems for vitreoretinal targets. Adv Drug Deliv Rev. 2005;57:2080-2091.
16. Nan K, Sun S, Li Y, et al. Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection. Br J Ophthalmol. 2010;94:654-658.
17. Veilleux-Lemieux D, Beaudry F, H́elie P, Vachon P. Effects of endotoxemia on the pharmacodynamics and pharmacokinetics of ketamine and xylazine anesthesia in Sprague-Dawley rats. Vet Med Res Rep. 2012;3:99-109.
18. Shen L, You Y, Sun S, Chen Y, Qu J, Cheng L. Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. Ophthalmology. 2010;117:2365-2371.
19. Davson H, Luck CP. Chemistry and rate of turnover of the ocular fluids of the bush baby (Galago crassicaudatus Agisymbanus). J Physiol. 1959;145:433-439.
20. Bill A. Conventional and uveo-scleral drainage of aqueous humour in the cynomolgus monkey (Macaca irus) at normal and high intraocular pressures. Exp Eye Res. 1966;5:45-54.
21. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol. 2003;121:667-673.
22. Kim JE, Pollack JS, Miller DG, Mittra RA, Spaide RF. ISIS-DME: a prospective, randomized, dose-escalation intravitreal steroid injection study for refractory diabetic macular edema. Retina. 2008;28:735-740.
23. Cheng L, Banker AS, Martin M, Kozak I, Freeman WR. Triamcinolone acetonide concentration of aqueous humor after decanted 20-mg intravitreal injection. Ophthalmology. 2009;116:1356-1359.
24. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB III, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681-686.
25. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447-1449.
26. Rojas C, Nagaraja NV, Derendorf H. In vitro recovery of triamcinolone acetonide in microdialysis. Pharmazie. 2000; 55:659-662.
27. Xu J, Heys JJ, Barocas VH, Randolph TW. Permeability and diffusion in vitreous humor: implications for drug delivery. Pharm Res. 2000;17:664-669.
28. Kim H, Csaky KG, Gravlin L, et al. Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina. 2006;26:523-530.